General
Preferred name
GLECAPREVIR
Synonyms
ABT-493 ()
A-1282576.0 ()
A-1282576 ()
A-12825760 ()
P&D ID
PD060940
CAS
1365970-03-1
Tags
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2017
Drug Status
investigational
approved
Drug indication
Chronic hepatitis C infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION
Indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh; A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor; or an NS3/4A protease inhibitor (PI), but not both [FDA Label].
DESCRIPTION
Glecaprevir is an orally available anti-hepatitis C virus (HCV) drug. It is a direct-acting inhibitor of the HCV NS3/4A protease, and thereby targets viral RNA replication.
(GtoPdb)
DESCRIPTION
Glecaprevir is a suppressive agent of hepatitis C virus (HCV). Glecaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 4.09 μM.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
1
Compound Sets
15
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
19
Molecular Weight
838.3
Hydrogen Bond Acceptors
11
Hydrogen Bond Donors
3
Rotatable Bonds
6
Ring Count
7
Aromatic Ring Count
2
cLogP
3.86
TPSA
195.22
Fraction CSP3
0.63
Chiral centers
8.0
Largest ring
18.0
QED
0.28
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Therapeutic Class
Antiviral Agent
Pathway
Anti-infection
Metabolic Enzyme/Protease
Target
HCV
HCV Protease
SARS-CoV
Solubility
Soluble in DMSO (Slightly), Methanol (Slightly)
Source data
